Net profit of Natco Pharma rose 83.55% to Rs 677.30 crore in the quarter ended September 2024 as against Rs 369.00 crore during the previous quarter ended September 2023. Sales rose 32.94% to Rs 1371.10 crore in the quarter ended September 2024 as against Rs 1031.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1371.101031.40 33 OPM %58.6644.41 - PBDT864.00483.20 79 PBT818.20439.60 86 NP677.30369.00 84 Powered by Capital Market - Live News

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 November 2024, inter alia, have recommended the second interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Natco Pharma has fixed 25 November 2024 as record date for 2nd interim dividend of Rs 1.50 per share for FY 2024-25. The dividend will be paid on 02 December 2024. Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live News

Natco Pharma announced that its wholly owned Canadian subsidiary, Natco Pharma (Canada) Inc. has made an investment of US$ 8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and effective humancompatible organs for transplant. In March 2024, eGenesis announced the world`s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN�) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant.Powered by Capital Market - Live News